13,052 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Bought by Wellington Management Group LLP

Wellington Management Group LLP purchased a new position in shares of Korro Bio, Inc. (NASDAQ:KRRO - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 13,052 shares of the company's stock, valued at approximately $436,000. Wellington Management Group LLP owned 0.14% of Korro Bio as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of KRRO. Brown Brothers Harriman & Co. bought a new position in shares of Korro Bio during the 2nd quarter worth approximately $28,000. Quest Partners LLC raised its stake in Korro Bio by 172.1% in the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company's stock valued at $59,000 after acquiring an additional 1,124 shares during the period. MetLife Investment Management LLC lifted its holdings in Korro Bio by 129.0% during the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company's stock valued at $122,000 after purchasing an additional 2,050 shares during the last quarter. Lynx1 Capital Management LP bought a new position in Korro Bio during the second quarter worth $129,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Korro Bio by 1,018.2% in the third quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company's stock valued at $164,000 after purchasing an additional 4,470 shares during the last quarter. Institutional investors and hedge funds own 13.18% of the company's stock.

Insider Activity at Korro Bio

In related news, CFO Vineet Agarwal sold 800 shares of Korro Bio stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $70.00, for a total value of $56,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.40% of the stock is owned by insiders.

Korro Bio Stock Up 1.3 %

Shares of KRRO traded up $0.55 during mid-day trading on Friday, hitting $43.67. 78,785 shares of the company's stock were exchanged, compared to its average volume of 75,541. Korro Bio, Inc. has a 52 week low of $30.00 and a 52 week high of $98.00. The stock's 50-day simple moving average is $55.74 and its 200-day simple moving average is $46.01.

Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.26) EPS for the quarter, topping analysts' consensus estimates of ($2.55) by $0.29. Equities research analysts forecast that Korro Bio, Inc. will post -9.63 EPS for the current year.

Analysts Set New Price Targets

KRRO has been the subject of a number of research reports. William Blair restated an "outperform" rating on shares of Korro Bio in a research note on Wednesday, November 13th. Royal Bank of Canada raised their price objective on shares of Korro Bio from $95.00 to $105.00 and gave the stock an "outperform" rating in a research report on Monday, October 21st. Raymond James initiated coverage on Korro Bio in a research report on Monday, October 21st. They issued a "strong-buy" rating and a $153.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $115.00 price target on shares of Korro Bio in a report on Friday, November 22nd. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $142.17.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).